4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions

This study has been completed.
Sponsor:
Information provided by:
Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT00121329
First received: July 13, 2005
Last updated: July 19, 2005
Last verified: July 2005
  Purpose

Recent studies have investigated the use of local anesthetics (i.e. lidocaine, mepivacaine) to lessen the pain experienced with minor gynecologic procedures such as endometrial biopsy and office hysteroscopy. Local anesthetic injected into the uterine cavity has been demonstrated effective in some studies at decreasing patient pain associated with these intrauterine procedures at an anesthetic concentration of at least 2%. Based on this evidence, we hypothesized that an intrauterine lidocaine infusion may reduce patient pain during first trimester abortions.


Condition Intervention
Pain
Drug: Intrauterine lidocaine infusion 4%

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: 4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions

Resource links provided by NLM:


Further study details as provided by Oregon Health and Science University:

Primary Outcome Measures:
  • VAS scores during cervical dilation and uterine aspiration

Secondary Outcome Measures:
  • Patient satisfaction, symptoms, lidocaine levels

Estimated Enrollment: 80
Estimated Study Completion Date: December 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age > 18 years old
  • Good general health
  • English speaking
  • Confirmation of gestational age by ultrasound
  • Body weight > 100 lbs.
  • Pregnancy < 11 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00121329

Locations
United States, Oregon
Planned Parenthood of the Columbia Willamette
Portland, Oregon, United States, 97206
Sponsors and Collaborators
Oregon Health and Science University
Investigators
Principal Investigator: Alison B Edelman, MD, MPH Oregon Health and Science University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00121329     History of Changes
Other Study ID Numbers: OHSU IRB 6876
Study First Received: July 13, 2005
Last Updated: July 19, 2005
Health Authority: United States: Institutional Review Board

Keywords provided by Oregon Health and Science University:
Pain with procedures

Additional relevant MeSH terms:
Lidocaine
Anesthetics
Anesthetics, Local
Anti-Arrhythmia Agents
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Sodium Channel Blockers
Therapeutic Uses
Voltage-Gated Sodium Channel Blockers

ClinicalTrials.gov processed this record on October 20, 2014